Successful treatment of Acute Fulminant Liver Failure due to Hepatitis B virus with Entecavir in patients with contra-indications to liver transplant
There are no randomized clinical trials on efficacy of Entecavir in Fulminant Hepatic Failure (FHF) due to Hepatitis B Virus (HBV). Definitive treatment of FHF remains Liver Transplant. However, availability of cadaveric donor organs is limited, and many of the patients with FHF may not be candidates for Liver Transplantation. There are only few case reports on beneficial effects of Entecavir in FHF due to HBV. We present 2 cases of FHF due to HBV. Both patients had severe liver cell damage among which one was immunocompromised. Transaminases were elevated up to 200 times the normal. Both were not transplant candidates, and were successfully treated with Entecavir resulting in significant clinical and transaminases improvement within 7 days of starting Entecavir.
Journal of Advances in Internal Medicine 2013;02(02):67-70